Merrill reiterates Cubist at buy

Cubist Pharmaceuticals Inc: was reiterated at a buy by Merrill Lynch analyst David Munno on expectations that the Food and Drug Administration will approve a label expansion for Cubicin by the March 24 PDUFA date. The analyst modeled theoretical values for Cubist based on three different labeling scenarios: Broad label, estimate a fair value of $44; Cubicin for bacteremia in endocarditis, suggest a fair value of about $33; and a restrictive label limiting Cubicin use, possible fair value of $17 to $22. Shares of the Lexington, Mass., pharmaceutical company were up 29 cents, or 1.17%, at $25.00 on volume of 640,916 shares versus the three-month running average of 745,148 shares. (Nasdaq: CBST)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.